![]() | |
Company type | Private |
---|---|
Industry | Health |
Founded | 2013 |
Founder |
|
Headquarters | Emeryville, CA |
Number of employees | 153 |
Website | www |
Eko Health Inc. (Eko) is an American healthcare technology company that develops medical devices, software, and clinical support AI to aid in the detection of cardiovascular and pulmonary diseases. [1]
Eko was founded in 2013 by Connor Landgraf, Jason Bellet, and Tyler Crouch. Landgraf was inspired to create Eko after seeing the limitations of traditional stethoscopes during his studies in biomedical engineering at the University of California, Berkeley and recruited his classmates Bellet and Crouch to join him. [2]
In 2015, Eko received FDA clearance for its first product, CORE, a digital attachment for traditional stethoscopes with a compatible smartphone application. [3]
In 2015, CORE was named one of TIME Magazine’s Best Inventions. [4]
In 2017, Eko received FDA clearance for the DUO, a combined digital stethoscope ECG that could be used without a traditional stethoscope. [5]
In 2018, Eko's low ejection fraction screening algorithm, developed with the Mayo Clinic, received a ‘Breakthrough Device’ designation from the FDA. [6]
In 2020, Eko announced $65 million in funding, [7] and a collaboration with 3M. [8] Eko raised an additional $30M in funding in 2022, [9] and received FDA clearance for its murmur analysis software. [10]
In 2023, Eko received FDA-clearance for the CORE500 digital stethoscope, which combines artificial intelligence (AI) software, high-fidelity audio, full-color display and 3-lead electrocardiogram (ECG). CORE500 offers compatibility with Eko’s Sensora platform, which uses artificial intelligence (AI) in cardiac disease detection. [11]
In April 2024, the company received FDA clearance for its low ejection fraction AI algorithm, developed in collaboration with the Mayo Clinic, enabling early detection of heart failure during routine physical exams. [12]
In June 2024, Eko secured $41 million in Series D financing, led by ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, to expand its AI-driven cardiac screening tools internationally. [13]
In November 2024, the American Medical Association (AMA) granted a Category III CPT code to Eko's Sensora AI platform. [14]